Every Woman Study™ 2023

Share this page

The Widening Gap

The World Ovarian Cancer Coalition’s 2018 online Every Woman StudyTM captured data from 1531 women with ovarian cancer in 44 countries. Results published in 2020 showed wide variations globally on key patient experience metrics, revealing many opportunities for improvement.  However, a limitation of the Study was a lack of sufficient data from low- and middle-income countries.

GLOBOCAN projects that ovarian cancer incidence will rise almost 40% by 2040 with developing countries bearing the greatest burden. Furthermore, 70% of women diagnosed each year live in low- or middle-income countries, where overall data about the burden of the disease is insufficient to guide public-health priorities.

Working with our partner, the International Gynecologic Cancer Society, the objective of this new initiative is to document for the first time ever, on this scale, the experiences of women with ovarian cancer in up to 30 low- and middle-income countries from pre-diagnosis through post-treatment. Initial results are expected in second half of 2023.

Co-Chairs & Leadership

The Oversight Committee is lead by Co-Chairs Dr. Tracey Sheridan Adams of Groote Schuur Hospital, Cape Town, South Africa and Robin Cohen, Vice-Chair of the Coalition and CEO of the Sandy Rollman Ovarian Cancer Foundation in the United States.

Frances Reid, Programme Director of the Coalition is serving as Study Lead and Coalition CEO Clara MacKay and IGCS CEO Mary Eiken lead the project team.